Becton, Dickinson and Company (NYSE:BDX) Downgraded to Hold Rating by StockNews.com

Becton, Dickinson and Company (NYSE:BDX) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a report released on Wednesday.

A number of other equities analysts have also issued reports on BDX. Evercore ISI upped their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price target for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $283.50.

Becton, Dickinson and Company Stock Down 0.7 %

Shares of NYSE BDX traded down $1.55 during trading on Wednesday, reaching $224.09. 3,387,297 shares of the stock were exchanged, compared to its average volume of 1,478,443. The business’s 50-day moving average price is $230.29 and its 200 day moving average price is $233.34. The company has a market capitalization of $64.79 billion, a price-to-earnings ratio of 37.73, a price-to-earnings-growth ratio of 1.64 and a beta of 0.41. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $249.89. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period last year, the firm earned $3.42 earnings per share. The company’s revenue was up 6.9% on a year-over-year basis. As a group, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Roland Goette sold 638 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the transaction, the executive vice president now directly owns 14,217 shares in the company, valued at $3,113,949.51. This represents a 4.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.31% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of hedge funds have recently added to or reduced their stakes in the stock. Livelsberger Financial Advisory acquired a new position in shares of Becton, Dickinson and Company during the third quarter worth approximately $26,000. Ashton Thomas Securities LLC bought a new stake in Becton, Dickinson and Company during the 3rd quarter valued at $33,000. Tompkins Financial Corp boosted its position in Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares during the period. Sound Income Strategies LLC grew its stake in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares in the last quarter. Finally, Abound Wealth Management increased its holdings in shares of Becton, Dickinson and Company by 96.0% during the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 96 shares during the period. 86.97% of the stock is currently owned by institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.